Frontiers in Neuroscience · 2019 · 46 citations · 39 references
Life SciencesMolecular BiologyNeuroscienceMolecular PathologyNeurobiology Of DiseaseNeurodegenerationCerebrospinal Fluid BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseProtein AggregationProtein MisfoldingAlpha-synuclein AggregationAlpha-synuclein BiomarkersAlpha-synuclein MisfoldingImmunoassaysMolecule CountingPost-translational Modification DetectionSingle-molecule CountingUltrasensitive Detection
Accumulation and aggregation of misfolded alpha-synuclein is believed to be a cause of Parkinson's disease (PD). Phosphorylation of alpha-synuclein at S129 is known to be associated with the pathological misfolding process, but efforts to investigate the relevance of this post-translational modification for pathology have been frustrated by difficulties in detecting and quantifying it in relevant samples. We report novel, ultrasensitive immunoassays based on single-molecule counting technology, useful for detecting alpha-synuclein and its S129 phosphorylated form in clinical samples in the low pg/ml range. Using human CSF and plasma samples, we find levels of alpha-synuclein comparable to those previously reported. However, while alpha-synuclein phosphorylated on S129 could easily be detected in human plasma, where its detection is extremely sensitive to protein phosphatases, its levels in CSF were undetectable, with a possible influence of a matrix effect. In plasma samples from a small test cohort comprising 5 PD individuals and five age-matched control individuals we find that pS129 alpha-synuclein levels are increased in PD plasma samples, in line with previous reports. We conclude that pS129 alpha-synuclein is not detectable in CSF and recommend the addition of phosphatase inhibitors to plasma samples at the time of collection. Moreover, the findings obtained on the small cohort of clinical plasma samples point to plasma pS129 alpha-synuclein levels as a candidate diagnostic biomarker in PD.
39
α-Synuclein is phosphorylated in synucleinopathy lesions
Hideo Fujiwara, Masato Hasegawa, Naoshi Dohmae et al. · Nature Cell Biology · 2002 · 2.2K citations
Limit of blank, limit of detection and limit of quantitation.
David Armbruster, Terry Pry · PubMed · 2008 · 2.1K citations · Full text
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Min Shi, Changqin Liu, Travis J. Cook et al. · Acta Neuropathologica · 2014 · 675 citations